Legislation Archives - Dehoney Financial Group

Patented Medicines Regulations Unveiled

Over two years ago, the federal government announced that the rules governing the pricing of pharmaceuticals in Canada were changing. Now, after a lengthy public consultation process with interested Canadians and stakeholders, including the pharmaceutical industry, the Government of Canada has announced the final amendments to the Patented Medicines Regulations aimed at saving “Canadians billions over the next decade.”

The Patented Medicine Prices Review Board (PMPRB) has introduced the following amendments:

In setting drug prices, a “basket” of 11 other countries (no longer including the US and Switzerland), that are similar to Canada’s population, economy and approach […]

Changes to OHIP+ Effective April 1, 2019

Patented Medicines Regulations

Recently, the Government of Ontario and insurer Industrial Alliance (IA) prepared some helpful information related to the upcoming changes to OHIP+. Our team assembled those details below to help our clients and plan administrators manage the transition.

APRIL 1, 2019 OHIP+ WILL NO LONGER COVER INDIVIDUALS 24 YEARS OLD AND UNDER WITH DRUG COVERAGE THROUGH A PRIVATE INSURANCE PLAN.

This is a major change to OHIP+ which impacts all youth aged 24 years and under covered by a private group insurance plan. Effective April 1, 2019 prescription drug claims must be submitted to a […]

Will modernizing the Patented Medicines Regulations in Canada lead to savings?

Patented Medicines Regulations

The Patented Medicines Regulations, those rules that govern the pricing of pharmaceuticals in Canada, are about to change. Many would suggest that it’s about time. There have been no substantive changes in over 20 years and Canada pays some of the highest drug prices when compared to countries of the Organisation for Economic Co-operation and Development (OECD). The United States and Mexico are the only two OECD countries that have higher patented drug prices than Canada.

The government’s proposal, titled Protecting Canadians from Excessive Drug Prices, sets out amendments to the current drug pricing regulations and may […]